Selected research
Industry Research
GFAP Antibody Industry Research Report 2026
Market perspective
The global GFAP Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the GFAP Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the GFAP Antibody market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the GFAP Antibody market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of GFAP Antibody include Merck, Synaptic Systems, Sino Biological, Santa Cruz Biotechnology, Proteintech, ProSci, Miltenyi Biotec, Hytest and GeneTex, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global GFAP Antibody market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to GFAP Antibody.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GFAP Antibody Market by Company
Merck
Synaptic Systems
Sino Biological
Santa Cruz Biotechnology
Proteintech
ProSci
Miltenyi Biotec
Hytest
GeneTex
FineTest
Enzo Life Sciences
EnCor Biotechnology
Aviva Systems Biology
Atlas Antibodies
GFAP Antibody Segment by Type
Polyclonal
Monoclonal
GFAP Antibody Segment by Application
Immunohistochemistry Paraffin
Immunohistochemistry Frozen
Immunofluorescence
Western Blot
Others
GFAP Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GFAP Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GFAP Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GFAP Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of GFAP Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Immunohistochemistry Paraffin
- Immunohistochemistry Frozen
- Immunofluorescence
- Western Blot
- Others
Companies covered
- Merck
- Synaptic Systems
- Sino Biological
- Santa Cruz Biotechnology
- Proteintech
- ProSci
- Miltenyi Biotec
- Hytest
- GeneTex
- FineTest
- Enzo Life Sciences
- EnCor Biotechnology
- Aviva Systems Biology
- Atlas Antibodies
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 GFAP Antibody by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Polyclonal
- 2.2.3 Monoclonal
- 2.3 GFAP Antibody by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Immunohistochemistry Paraffin
- 2.3.3 Immunohistochemistry Frozen
- 2.3.4 Immunofluorescence
- 2.3.5 Western Blot
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 GFAP Antibody Breakdown Data by Type
- 3.1 Global GFAP Antibody Historic Market Size by Type (2021-2026)
- 3.2 Global GFAP Antibody Forecasted Market Size by Type (2027-2032)
4 GFAP Antibody Breakdown Data by Application
- 4.1 Global GFAP Antibody Historic Market Size by Application (2021-2026)
- 4.2 Global GFAP Antibody Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global GFAP Antibody Market Perspective (2021-2032)
- 5.2 Global GFAP Antibody Growth Trends by Region
- 5.2.1 Global GFAP Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 GFAP Antibody Historic Market Size by Region (2021-2026)
- 5.2.3 GFAP Antibody Forecasted Market Size by Region (2027-2032)
- 5.3 GFAP Antibody Market Dynamics
- 5.3.1 GFAP Antibody Industry Trends
- 5.3.2 GFAP Antibody Market Drivers
- 5.3.3 GFAP Antibody Market Challenges
- 5.3.4 GFAP Antibody Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top GFAP Antibody Players by Revenue
- 6.1.1 Global Top GFAP Antibody Players by Revenue (2021-2026)
- 6.1.2 Global GFAP Antibody Revenue Market Share by Players (2021-2026)
- 6.2 Global GFAP Antibody Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of GFAP Antibody Head Office and Area Served
- 6.4 Global GFAP Antibody Players, Product Type & Application
- 6.5 Global GFAP Antibody Manufacturers Established Date
- 6.6 Global GFAP Antibody Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America GFAP Antibody Market Size (2021-2032)
- 7.2 North America GFAP Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America GFAP Antibody Market Size by Country (2021-2026)
- 7.4 North America GFAP Antibody Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe GFAP Antibody Market Size (2021-2032)
- 8.2 Europe GFAP Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe GFAP Antibody Market Size by Country (2021-2026)
- 8.4 Europe GFAP Antibody Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific GFAP Antibody Market Size (2021-2032)
- 9.2 Asia-Pacific GFAP Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific GFAP Antibody Market Size by Country (2021-2026)
- 9.4 Asia-Pacific GFAP Antibody Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America GFAP Antibody Market Size (2021-2032)
- 10.2 South America GFAP Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America GFAP Antibody Market Size by Country (2021-2026)
- 10.4 South America GFAP Antibody Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa GFAP Antibody Market Size (2021-2032)
- 11.2 Middle East & Africa GFAP Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa GFAP Antibody Market Size by Country (2021-2026)
- 11.4 Middle East & Africa GFAP Antibody Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in GFAP Antibody Business (2021-2026)
- 12.1.4 Merck GFAP Antibody Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 Synaptic Systems
- 12.2.1 Synaptic Systems Company Information
- 12.2.2 Synaptic Systems Business Overview
- 12.2.3 Synaptic Systems Revenue in GFAP Antibody Business (2021-2026)
- 12.2.4 Synaptic Systems GFAP Antibody Product Portfolio
- 12.2.5 Synaptic Systems Recent Developments
- 12.3 Sino Biological
- 12.3.1 Sino Biological Company Information
- 12.3.2 Sino Biological Business Overview
- 12.3.3 Sino Biological Revenue in GFAP Antibody Business (2021-2026)
- 12.3.4 Sino Biological GFAP Antibody Product Portfolio
- 12.3.5 Sino Biological Recent Developments
- 12.4 Santa Cruz Biotechnology
- 12.4.1 Santa Cruz Biotechnology Company Information
- 12.4.2 Santa Cruz Biotechnology Business Overview
- 12.4.3 Santa Cruz Biotechnology Revenue in GFAP Antibody Business (2021-2026)
- 12.4.4 Santa Cruz Biotechnology GFAP Antibody Product Portfolio
- 12.4.5 Santa Cruz Biotechnology Recent Developments
- 12.5 Proteintech
- 12.5.1 Proteintech Company Information
- 12.5.2 Proteintech Business Overview
- 12.5.3 Proteintech Revenue in GFAP Antibody Business (2021-2026)
- 12.5.4 Proteintech GFAP Antibody Product Portfolio
- 12.5.5 Proteintech Recent Developments
- 12.6 ProSci
- 12.6.1 ProSci Company Information
- 12.6.2 ProSci Business Overview
- 12.6.3 ProSci Revenue in GFAP Antibody Business (2021-2026)
- 12.6.4 ProSci GFAP Antibody Product Portfolio
- 12.6.5 ProSci Recent Developments
- 12.7 Miltenyi Biotec
- 12.7.1 Miltenyi Biotec Company Information
- 12.7.2 Miltenyi Biotec Business Overview
- 12.7.3 Miltenyi Biotec Revenue in GFAP Antibody Business (2021-2026)
- 12.7.4 Miltenyi Biotec GFAP Antibody Product Portfolio
- 12.7.5 Miltenyi Biotec Recent Developments
- 12.8 Hytest
- 12.8.1 Hytest Company Information
- 12.8.2 Hytest Business Overview
- 12.8.3 Hytest Revenue in GFAP Antibody Business (2021-2026)
- 12.8.4 Hytest GFAP Antibody Product Portfolio
- 12.8.5 Hytest Recent Developments
- 12.9 GeneTex
- 12.9.1 GeneTex Company Information
- 12.9.2 GeneTex Business Overview
- 12.9.3 GeneTex Revenue in GFAP Antibody Business (2021-2026)
- 12.9.4 GeneTex GFAP Antibody Product Portfolio
- 12.9.5 GeneTex Recent Developments
- 12.10 FineTest
- 12.10.1 FineTest Company Information
- 12.10.2 FineTest Business Overview
- 12.10.3 FineTest Revenue in GFAP Antibody Business (2021-2026)
- 12.10.4 FineTest GFAP Antibody Product Portfolio
- 12.10.5 FineTest Recent Developments
- 12.11 Enzo Life Sciences
- 12.11.1 Enzo Life Sciences Company Information
- 12.11.2 Enzo Life Sciences Business Overview
- 12.11.3 Enzo Life Sciences Revenue in GFAP Antibody Business (2021-2026)
- 12.11.4 Enzo Life Sciences GFAP Antibody Product Portfolio
- 12.11.5 Enzo Life Sciences Recent Developments
- 12.12 EnCor Biotechnology
- 12.12.1 EnCor Biotechnology Company Information
- 12.12.2 EnCor Biotechnology Business Overview
- 12.12.3 EnCor Biotechnology Revenue in GFAP Antibody Business (2021-2026)
- 12.12.4 EnCor Biotechnology GFAP Antibody Product Portfolio
- 12.12.5 EnCor Biotechnology Recent Developments
- 12.13 Aviva Systems Biology
- 12.13.1 Aviva Systems Biology Company Information
- 12.13.2 Aviva Systems Biology Business Overview
- 12.13.3 Aviva Systems Biology Revenue in GFAP Antibody Business (2021-2026)
- 12.13.4 Aviva Systems Biology GFAP Antibody Product Portfolio
- 12.13.5 Aviva Systems Biology Recent Developments
- 12.14 Atlas Antibodies
- 12.14.1 Atlas Antibodies Company Information
- 12.14.2 Atlas Antibodies Business Overview
- 12.14.3 Atlas Antibodies Revenue in GFAP Antibody Business (2021-2026)
- 12.14.4 Atlas Antibodies GFAP Antibody Product Portfolio
- 12.14.5 Atlas Antibodies Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst